{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T17:03:44Z","timestamp":1791392624320,"version":"4.3.3"},"reference-count":152,"publisher":"Walter de Gruyter GmbH","issue":"7","funder":[{"DOI":"10.13039\/501100018624","name":"Science and Technology Bureau of Quanzhou","doi-asserted-by":"crossref","award":["2020CT003"],"award-info":[{"award-number":["2020CT003"]}],"id":[{"id":"10.13039\/501100018624","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100018624","name":"Science and Technology Bureau of Quanzhou","doi-asserted-by":"crossref","award":["2019C075R"],"award-info":[{"award-number":["2019C075R"]}],"id":[{"id":"10.13039\/501100018624","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100018624","name":"Science and Technology Bureau of Quanzhou","doi-asserted-by":"crossref","award":["2022C025R"],"award-info":[{"award-number":["2022C025R"]}],"id":[{"id":"10.13039\/501100018624","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100005270","name":"Fujian Provincial Department of Science and Technology","doi-asserted-by":"crossref","award":["2019J01164"],"award-info":[{"award-number":["2019J01164"]}],"id":[{"id":"10.13039\/501100005270","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100017686","name":"Fujian Provincial Health Technology Project","doi-asserted-by":"crossref","award":["2019-1-54"],"award-info":[{"award-number":["2019-1-54"]}],"id":[{"id":"10.13039\/501100017686","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Natural Science Foundation of Fujian Province,China","award":["2022J01793"],"award-info":[{"award-number":["2022J01793"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,10,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Parkinson\u2019s disease (PD) is one of the most widespread neurodegenerative diseases. PD is associated with progressive loss of substantia nigra dopaminergic neurons, including various motor symptoms (e.g., bradykinesia, rigidity, and resting tremor), as well as non-motor symptoms (e.g., cognitive impairment, constipation, fatigue, sleep disturbance, and depression). PD involves multiple biological processes, including mitochondrial or lysosomal dysfunction, oxidative stress, insulin resistance, and neuroinflammation. Metabolic syndrome (MetS), a collection of numerous connected cerebral cardiovascular conditions, is a common and growing public health problem associated with many chronic diseases worldwide. MetS components include central\/abdominal obesity, systemic hypertension, diabetes, and atherogenic dyslipidemia. MetS and PD share multiple pathophysiological processes, including insulin resistance, oxidative stress, and chronic inflammation. In recent years, MetS has been linked to an increased risk of PD,\u00a0according to studies; however, the specific mechanism remains unclear. Researchers also found that some related metabolic therapies are potential therapeutic strategies to prevent and improve PD. This article reviews the epidemiological relationship between components of MetS and the risk of PD and discusses the potentially relevant mechanisms and recent progress of MetS as a risk factor for PD. Furthermore, we conclude that MetS-related therapies are beneficial for the prevention and treatment of PD.<\/jats:p>","DOI":"10.1515\/revneuro-2022-0093","type":"journal-article","created":{"date-parts":[[2022,11,30]],"date-time":"2022-11-30T23:41:42Z","timestamp":1669851702000},"page":"719-735","source":"Crossref","is-referenced-by-count":26,"title":["Recent research progress on metabolic syndrome and risk of Parkinson\u2019s disease"],"prefix":"10.1515","volume":"34","author":[{"given":"Lin-yi","family":"Li","sequence":"first","affiliation":[{"name":"Department of Neurology , The Second Affiliated Hospital, Fujian Medical University , No. 34 North Zhongshan Road , Quanzhou 362000 , Fujian Province , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-fen","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Neurology , The Second Affiliated Hospital, Fujian Medical University , No. 34 North Zhongshan Road , Quanzhou 362000 , Fujian Province , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-long","family":"Zhuang","sequence":"additional","affiliation":[{"name":"Prenatal Diagnosis Center, Quanzhou Women\u2019s and Children\u2019s Hospital , Quanzhou 362000 , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mi-mi","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Neurology , The Second Affiliated Hospital, Fujian Medical University , No. 34 North Zhongshan Road , Quanzhou 362000 , Fujian Province , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng-ping","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Neurology , The Second Affiliated Hospital, Fujian Medical University , No. 34 North Zhongshan Road , Quanzhou 362000 , Fujian Province , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-hong","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Neurology , Shishi General Hospital , Quanzhou 362000 , Fujian Province , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang-rong","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery , The Second Affiliated Hospital, Fujian Medical University , Quanzhou 362000 , Fujian Province , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-nuan","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Neurology , The Second Affiliated Hospital, Fujian Medical University , No. 34 North Zhongshan Road , Quanzhou 362000 , Fujian Province , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu","family":"Lin","sequence":"additional","affiliation":[{"name":"Centre of Neurological and Metabolic Research, The Second Affiliated Hospital of Fujian Medical University , Quanzhou 362000 , Fujian Province , China"},{"name":"Group of Neuroendocrinology, Garvan Institute of Medical Research , 384 Victoria St, Sydney , NSW , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-chao","family":"Ye","sequence":"additional","affiliation":[{"name":"Department of Neurology , The Second Affiliated Hospital, Fujian Medical University , No. 34 North Zhongshan Road , Quanzhou 362000 , Fujian Province , China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2022,12,2]]},"reference":[{"key":"2023100409531721958_j_revneuro-2022-0093_ref_002","doi-asserted-by":"crossref","unstructured":"Abbott, R.D., Ross, G.W., White, L.R., Nelson, J.S., Masaki, K.H., Tanner, C.M., Curb, J.D., Blanchette, P.L., Popper, J.S., and Petrovitch, H. (2002). Midlife adiposity and the future risk of Parkinson\u2019s disease. Neurology 59: 1051\u20131057, https:\/\/doi.org\/10.1212\/wnl.59.7.1051.","DOI":"10.1212\/WNL.59.7.1051"},{"key":"2023100409531721958_j_revneuro-2022-0093_ref_003","doi-asserted-by":"crossref","unstructured":"Abdelsalam, R.M. and Safar, M.M. (2015). Neuroprotective effects of vildagliptin in rat rotenone Parkinson\u2019s disease model: role of RAGE-NF\u03baB and Nrf2-antioxidant signaling pathways. J.\u00a0Neurochem. 133: 700\u2013707, https:\/\/doi.org\/10.1111\/jnc.13087.","DOI":"10.1111\/jnc.13087"},{"key":"2023100409531721958_j_revneuro-2022-0093_ref_004","doi-asserted-by":"crossref","unstructured":"Armutcu, F., Ataymen, M., Atmaca, H., and Gurel, A. (2008). Oxidative stress markers, C-reactive protein and heat shock protein 70 levels in subjects with metabolic syndrome. Clin. Chem. Lab. Med. 46: 785\u2013790, https:\/\/doi.org\/10.1515\/cclm.2008.166.","DOI":"10.1515\/CCLM.2008.166"},{"key":"2023100409531721958_j_revneuro-2022-0093_ref_005","doi-asserted-by":"crossref","unstructured":"Athauda, D., Maclagan, K., Skene, S.S., Bajwa-Joseph, M., Letchford, D., Chowdhury, K., Hibbert, S., Budnik, N., Zampedri, L., Dickson, J., et al.. (2017). Exenatide once weekly versus placebo in Parkinson\u2019s disease: a randomised, double-blind, placebo-controlled trial. Lancet 390: 1664\u20131675, https:\/\/doi.org\/10.1016\/s0140-6736(17)31585-4.","DOI":"10.1016\/S0140-6736(17)31585-4"},{"key":"2023100409531721958_j_revneuro-2022-0093_ref_006","doi-asserted-by":"crossref","unstructured":"Aviles-Olmos, I., Limousin, P., Lees, A., and Foltynie, T. (2013). Parkinson\u2019s disease, insulin resistance and novel agents of neuroprotection. Brain 136: 374\u2013384, https:\/\/doi.org\/10.1093\/brain\/aws009.","DOI":"10.1093\/brain\/aws009"},{"key":"2023100409531721958_j_revneuro-2022-0093_ref_007","doi-asserted-by":"crossref","unstructured":"Aytan, N., Jung, T., Tamt\u00fcrk, F., Grune, T., and Kartal-Ozer, N. (2008). Oxidative stress related changes in the brain of hypercholesterolemic rabbits. Biofactors 33: 225\u2013236, https:\/\/doi.org\/10.1002\/biof.5520330308.","DOI":"10.1002\/biof.5520330308"},{"key":"2023100409531721958_j_revneuro-2022-0093_ref_008","doi-asserted-by":"crossref","unstructured":"Baggio, L.L. and Drucker, D.J. (2007). Biology of incretins: GLP-1 and GIP. Gastroenterology 132: 2131\u20132157, https:\/\/doi.org\/10.1053\/j.gastro.2007.03.054.","DOI":"10.1053\/j.gastro.2007.03.054"},{"key":"2023100409531721958_j_revneuro-2022-0093_ref_009","doi-asserted-by":"crossref","unstructured":"Baron, A.D. (1994). Hemodynamic actions of insulin. Am. J.\u00a0Physiol. 267: E187\u2013E202, https:\/\/doi.org\/10.1152\/ajpendo.1994.267.2.e187.","DOI":"10.1152\/ajpendo.1994.267.2.E187"},{"key":"2023100409531721958_j_revneuro-2022-0093_ref_010","doi-asserted-by":"crossref","unstructured":"Bassil, F., Fernagut, P.O., Bezard, E., and Meissner, W.G. (2014). Insulin, IGF-1 and GLP-1 signaling in neurodegenerative disorders: targets for disease modification. Prog. Neurobiol. 118: 1\u201318, https:\/\/doi.org\/10.1016\/j.pneurobio.2014.02.005.","DOI":"10.1016\/j.pneurobio.2014.02.005"},{"key":"2023100409531721958_j_revneuro-2022-0093_ref_011","doi-asserted-by":"crossref","unstructured":"Blackburn, J.K., Curry, D.W., Thomsen, A.N., Roth, R.H., and Elsworth, J.D. (2020). Pioglitazone activates paraoxonase-2 in the brain: a novel neuroprotective mechanism. Exp. Neurol. 327: 113234, https:\/\/doi.org\/10.1016\/j.expneurol.2020.113234.","DOI":"10.1016\/j.expneurol.2020.113234"},{"key":"2023100409531721958_j_revneuro-2022-0093_ref_012","doi-asserted-by":"crossref","unstructured":"Blackburn, J.K., Jamwal, S., Wang, W., and Elsworth, J.D. (2022). Pioglitazone transiently stimulates paraoxonase-2 expression in male nonhuman primate brain: implications for sex-specific therapeutics in neurodegenerative disorders. Neurochem. Int. 152: 105222, https:\/\/doi.org\/10.1016\/j.neuint.2021.105222.","DOI":"10.1016\/j.neuint.2021.105222"},{"key":"2023100409531721958_j_revneuro-2022-0093_ref_013","doi-asserted-by":"crossref","unstructured":"Blesa, J., Trigo-Damas, I., Quiroga-Varela, A., and Jackson-Lewis, V.R. (2015). Oxidative stress and Parkinson\u2019s disease. Front. Neuroanat. 9: 91, https:\/\/doi.org\/10.3389\/fnana.2015.00091.","DOI":"10.3389\/fnana.2015.00091"},{"key":"2023100409531721958_j_revneuro-2022-0093_ref_014","doi-asserted-by":"crossref","unstructured":"Boden, G. (1998). Free fatty acids (FFA), a link between obesity and insulin resistance. Front. Biosci. 3: d169\u2013d175, https:\/\/doi.org\/10.2741\/a272.","DOI":"10.2741\/A272"},{"key":"2023100409531721958_j_revneuro-2022-0093_ref_015","doi-asserted-by":"crossref","unstructured":"Bosco, D.A., Fowler, D.M., Zhang, Q., Nieva, J., Powers, E.T., WentworthJr, P., Lerner, R.A., and Kelly, J.W. (2006). Elevated levels of oxidized cholesterol metabolites in Lewy body disease brains accelerate alpha-synuclein fibrilization. Nat. Chem. Biol. 2: 249\u2013253, https:\/\/doi.org\/10.1038\/nchembio782.","DOI":"10.1038\/nchembio782"},{"key":"2023100409531721958_j_revneuro-2022-0093_ref_016","doi-asserted-by":"crossref","unstructured":"Braak, H., Del Tredici, K., R\u00fcb, U., de Vos, R.A., Jansen Steur, E.N., and Braak, E. (2003). Staging of brain pathology related to sporadic Parkinson\u2019s disease. Neurobiol. Aging 24: 197\u2013211, https:\/\/doi.org\/10.1016\/s0197-4580(02)00065-9.","DOI":"10.1016\/S0197-4580(02)00065-9"},{"key":"2023100409531721958_j_revneuro-2022-0093_ref_017","doi-asserted-by":"crossref","unstructured":"Caccamo, A., Majumder, S., Richardson, A., Strong, R., and Oddo, S. (2010). Molecular interplay between mammalian target of rapamycin (mTOR), amyloid-beta, and Tau: effects on cognitive impairments. J.\u00a0Biol. Chem. 285: 13107\u201313120, https:\/\/doi.org\/10.1074\/jbc.m110.100420.","DOI":"10.1074\/jbc.M110.100420"},{"key":"2023100409531721958_j_revneuro-2022-0093_ref_018","doi-asserted-by":"crossref","unstructured":"Canal, M., Roman\u00ed-Aumedes, J., Mart\u00edn-Flores, N., P\u00e9rez-Fern\u00e1ndez, V., and Malagelada, C. (2014). RTP801\/REDD1: a stress coping regulator that turns into a troublemaker in neurodegenerative disorders. Front. Cell Neurosci. 8: 313, https:\/\/doi.org\/10.3389\/fncel.2014.00313.","DOI":"10.3389\/fncel.2014.00313"},{"key":"2023100409531721958_j_revneuro-2022-0093_ref_019","doi-asserted-by":"crossref","unstructured":"Cani, P.D., Amar, J., Iglesias, M.A., Poggi, M., Knauf, C., Bastelica, D., Neyrinck, A.M., Fava, F., Tuohy, K.M., Chabo, C., et al.. (2007). Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 56: 1761\u20131772, https:\/\/doi.org\/10.2337\/db06-1491.","DOI":"10.2337\/db06-1491"},{"key":"2023100409531721958_j_revneuro-2022-0093_ref_020","doi-asserted-by":"crossref","unstructured":"Carroll, C.B. and Wyse, R. (2017). Simvastatin as a potential disease-modifying therapy for patients with Parkinson\u2019s disease: rationale for clinical trial, and current progress. J.\u00a0Parkinson\u2019s Dis. 7: 545\u2013568, https:\/\/doi.org\/10.3233\/jpd-171203.","DOI":"10.3233\/JPD-171203"},{"key":"2023100409531721958_j_revneuro-2022-0093_ref_021","doi-asserted-by":"crossref","unstructured":"Chang, Y.H., Yen, S.J., Chang, Y.H., Wu, W.J., and Lin, K.D. (2021). Pioglitazone and statins lower incidence of Parkinson disease in patients with diabetes mellitus. Eur. J.\u00a0Neurol. 28: 430\u2013437, https:\/\/doi.org\/10.1111\/ene.14542.","DOI":"10.1111\/ene.14542"},{"key":"2023100409531721958_j_revneuro-2022-0093_ref_022","doi-asserted-by":"crossref","unstructured":"Chen, J., Zhang, C., Wu, Y., and Zhang, D. (2019). Association between hypertension and the risk of Parkinson\u2019s disease: a meta-analysis of analytical studies. Neuroepidemiology 52: 181\u2013192, https:\/\/doi.org\/10.1159\/000496977.","DOI":"10.1159\/000496977"},{"key":"2023100409531721958_j_revneuro-2022-0093_ref_023","doi-asserted-by":"crossref","unstructured":"Chiurchi\u00f9, V. and Maccarrone, M. (2011). Chronic inflammatory disorders and their redox control: from molecular mechanisms to therapeutic opportunities. Antioxid. Redox Signaling 15: 2605\u20132641, https:\/\/doi.org\/10.1089\/ars.2010.3547.","DOI":"10.1089\/ars.2010.3547"},{"key":"2023100409531721958_j_revneuro-2022-0093_ref_024","doi-asserted-by":"crossref","unstructured":"Chohan, H., Senkevich, K., Patel, R.K., Bestwick, J.P., Jacobs, B.M., Bandres Ciga, S., Gan-Or, Z., and Noyce, A.J. (2021). Type 2 diabetes as a determinant of Parkinson\u2019s disease risk and progression. Mov. Disord. 36: 1420\u20131429, https:\/\/doi.org\/10.1002\/mds.28551.","DOI":"10.1002\/mds.28551"},{"key":"2023100409531721958_j_revneuro-2022-0093_ref_025","doi-asserted-by":"crossref","unstructured":"Cornier, M.A., Dabelea, D., Hernandez, T.L., Lindstrom, R.C., Steig, A.J., Stob, N.R., Van Pelt, R.E., Wang, H., and Eckel, R.H. (2008). The metabolic syndrome. Endocr. Rev. 29: 777\u2013822, https:\/\/doi.org\/10.1210\/er.2008-0024.","DOI":"10.1210\/er.2008-0024"},{"key":"2023100409531721958_j_revneuro-2022-0093_ref_026","doi-asserted-by":"crossref","unstructured":"Czech, M.P. (2017). Insulin action and resistance in obesity and type 2 diabetes. Nat. Med. 23: 804\u2013814, https:\/\/doi.org\/10.1038\/nm.4350.","DOI":"10.1038\/nm.4350"},{"key":"2023100409531721958_j_revneuro-2022-0093_ref_076","doi-asserted-by":"crossref","unstructured":"de Lau, L.M., Koudstaal, P.J., Hofman, A., and Breteler, M.M. (2006). Serum cholesterol levels and the risk of Parkinson\u2019s disease. Am. J.\u00a0Epidemiol. 164: 998\u20131002, https:\/\/doi.org\/10.1093\/aje\/kwj283.","DOI":"10.1093\/aje\/kwj283"},{"key":"2023100409531721958_j_revneuro-2022-0093_ref_027","doi-asserted-by":"crossref","unstructured":"Dominguez, L.J., Barbagallo, M., Mu\u00f1oz-Garcia, M., Godos, J., and Martinez-Gonzalez, M.A. (2019). Dietary patterns and cognitive decline: key features for prevention. Curr. Pharm. Des. 25: 2428\u20132442, https:\/\/doi.org\/10.2174\/1381612825666190722110458.","DOI":"10.2174\/1381612825666190722110458"},{"key":"2023100409531721958_j_revneuro-2022-0093_ref_028","doi-asserted-by":"crossref","unstructured":"Dresner, A., Laurent, D., Marcucci, M., Griffin, M.E., Dufour, S., Cline, G.W., Slezak, L.A., Andersen, D.K., Hundal, R.S., Rothman, D.L., et al.. (1999). Effects of free fatty acids on glucose transport and IRS-1-associated phosphatidylinositol 3-kinase activity. J.\u00a0Clin. Invest. 103: 253\u2013259, https:\/\/doi.org\/10.1172\/jci5001.","DOI":"10.1172\/JCI5001"},{"key":"2023100409531721958_j_revneuro-2022-0093_ref_029","doi-asserted-by":"crossref","unstructured":"Driver, J.A., Smith, A., Buring, J.E., Gaziano, J.M., Kurth, T., and Logroscino, G. (2008). Prospective cohort study of type 2 diabetes and the risk of Parkinson\u2019s disease. Diabetes Care 31: 2003\u20132005, https:\/\/doi.org\/10.2337\/dc08-0688.","DOI":"10.2337\/dc08-0688"},{"key":"2023100409531721958_j_revneuro-2022-0093_ref_030","doi-asserted-by":"crossref","unstructured":"Duarte, A.I., Moreira, P.I., and Oliveira, C.R. (2012). Insulin in central nervous system: more than just a peripheral hormone. J.\u00a0Aging Res. 2012: 384017.","DOI":"10.1155\/2012\/384017"},{"key":"2023100409531721958_j_revneuro-2022-0093_ref_031","doi-asserted-by":"crossref","unstructured":"D\u00edez, J.J. and Iglesias, P. (2003). The role of the novel adipocyte-derived hormone adiponectin in human disease. Eur. J.\u00a0Endocrinol. 148: 293\u2013300, https:\/\/doi.org\/10.1530\/eje.0.1480293.","DOI":"10.1530\/eje.0.1480293"},{"key":"2023100409531721958_j_revneuro-2022-0093_ref_032","doi-asserted-by":"crossref","unstructured":"Elbassuoni, E.A. and Ahmed, R.F. (2019). Mechanism of the neuroprotective effect of GLP-1 in a rat model of Parkinson\u2019s with pre-existing diabetes. Neurochem. Int. 131: 104583, https:\/\/doi.org\/10.1016\/j.neuint.2019.104583.","DOI":"10.1016\/j.neuint.2019.104583"},{"key":"2023100409531721958_j_revneuro-2022-0093_ref_033","doi-asserted-by":"crossref","unstructured":"Fang, F., Zhan, Y., Hammar, N., Shen, X., Wirdefeldt, K., Walldius, G., and Mariosa, D. (2019). Lipids, apolipoproteins, and the risk of Parkinson disease. Circ. Res. 125: 643\u2013652, https:\/\/doi.org\/10.1161\/circresaha.119.314929.","DOI":"10.1161\/CIRCRESAHA.119.314929"},{"key":"2023100409531721958_j_revneuro-2022-0093_ref_034","doi-asserted-by":"crossref","unstructured":"Ferrer, I., Martinez, A., Blanco, R., Dalf\u00f3, E., and Carmona, M. (2011). Neuropathology of sporadic Parkinson disease before the appearance of parkinsonism: preclinical Parkinson disease. J.\u00a0Neural. Transm. (Vienna) 118: 821\u2013839, https:\/\/doi.org\/10.1007\/s00702-010-0482-8.","DOI":"10.1007\/s00702-010-0482-8"},{"key":"2023100409531721958_j_revneuro-2022-0093_ref_035","doi-asserted-by":"crossref","unstructured":"Floor, E. and Wetzel, M.G. (1998). Increased protein oxidation in human substantia nigra pars compacta in comparison with basal ganglia and prefrontal cortex measured with an improved dinitrophenylhydrazine assay. J.\u00a0Neurochem. 70: 268\u2013275, https:\/\/doi.org\/10.1046\/j.1471-4159.1998.70010268.x.","DOI":"10.1046\/j.1471-4159.1998.70010268.x"},{"key":"2023100409531721958_j_revneuro-2022-0093_ref_036","doi-asserted-by":"crossref","unstructured":"Ford, J.H. (2010). Saturated fatty acid metabolism is key link between cell division, cancer, and senescence in cellular and whole organism aging. Age (Dordr.) 32: 231\u2013237, https:\/\/doi.org\/10.1007\/s11357-009-9128-x.","DOI":"10.1007\/s11357-009-9128-x"},{"key":"2023100409531721958_j_revneuro-2022-0093_ref_037","doi-asserted-by":"crossref","unstructured":"Frederich, R.C., Hamann, A., Anderson, S., L\u00f6llmann, B., Lowell, B.B., and Flier, J.S. (1995). Leptin levels reflect body lipid content in mice: evidence for diet-induced resistance to leptin action. Nat. Med. 1: 1311\u20131314, https:\/\/doi.org\/10.1038\/nm1295-1311.","DOI":"10.1038\/nm1295-1311"},{"key":"2023100409531721958_j_revneuro-2022-0093_ref_038","doi-asserted-by":"crossref","unstructured":"Frost, R.J. and Olson, E.N. (2011). Control of glucose homeostasis and insulin sensitivity by the Let-7 family of microRNAs. Proc. Natl. Acad. Sci. U.S.A. 108: 21075\u201321080, https:\/\/doi.org\/10.1073\/pnas.1118922109.","DOI":"10.1073\/pnas.1118922109"},{"key":"2023100409531721958_j_revneuro-2022-0093_ref_039","doi-asserted-by":"crossref","unstructured":"Fu, X., Wang, Y., He, X., Li, H., Liu, H., and Zhang, X. (2020). A\u00a0systematic review and meta-analysis of serum cholesterol and triglyceride levels in patients with Parkinson\u2019s disease. Lipids Health Dis. 19: 97, https:\/\/doi.org\/10.1186\/s12944-020-01284-w.","DOI":"10.1186\/s12944-020-01284-w"},{"key":"2023100409531721958_j_revneuro-2022-0093_ref_040","unstructured":"GBD 2016 Neurology Collaborators (2019). Global, regional, and national burden of neurological disorders, 1990\u20132016: a\u00a0systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 18: 459\u2013480."},{"key":"2023100409531721958_j_revneuro-2022-0093_ref_041","doi-asserted-by":"crossref","unstructured":"Garc\u00eda-Sanz, P., Aerts, M.F.G.J., and Moratalla, R. (2021). The role of cholesterol in \u03b1-synuclein and Lewy body pathology in GBA1 Parkinson\u2019s disease. Mov. Disord. 36: 1070\u20131085, https:\/\/doi.org\/10.1002\/mds.28396.","DOI":"10.1002\/mds.28396"},{"key":"2023100409531721958_j_revneuro-2022-0093_ref_042","doi-asserted-by":"crossref","unstructured":"Ghosh, A., Tyson, T., George, S., Hildebrandt, E.N., Steiner, J.A., Madaj, Z., Schulz, E., Machiela, E., McDonald, W.G., Escobar Galvis, M.L., et al.. (2016). Mitochondrial pyruvate carrier regulates autophagy, inflammation, and neurodegeneration in experimental models of Parkinson\u2019s disease. Sci. Transl. Med. 8: 368ra174, https:\/\/doi.org\/10.1126\/scitranslmed.aag2210.","DOI":"10.1126\/scitranslmed.aag2210"},{"key":"2023100409531721958_j_revneuro-2022-0093_ref_043","doi-asserted-by":"crossref","unstructured":"Goedert, M., Masuda-Suzukake, M., and Falcon, B. (2017). Like prions: the propagation of aggregated tau and \u03b1-synuclein in neurodegeneration. Brain 140: 266\u2013278, https:\/\/doi.org\/10.1093\/brain\/aww230.","DOI":"10.1093\/brain\/aww230"},{"key":"2023100409531721958_j_revneuro-2022-0093_ref_044","doi-asserted-by":"crossref","unstructured":"Goh, S.Y., Chao, Y.X., Dheen, S.T., Tan, E.K., and Tay, S.S. (2019). Role of MicroRNAs in Parkinson\u2019s disease. Int. J.\u00a0Mol. Sci. 20: 5649, https:\/\/doi.org\/10.3390\/ijms20225649.","DOI":"10.3390\/ijms20225649"},{"key":"2023100409531721958_j_revneuro-2022-0093_ref_045","doi-asserted-by":"crossref","unstructured":"Golpich, M., Amini, E., Hemmati, F., Ibrahim, N.M., Rahmani, B., Mohamed, Z., Raymond, A.A., Dargahi, L., Ghasemi, R., and Ahmadiani, A. (2015). Glycogen synthase kinase-3 beta (GSK-3\u03b2) signaling: implications for Parkinson\u2019s disease. Pharmacol. Res. 97: 16\u201326, https:\/\/doi.org\/10.1016\/j.phrs.2015.03.010.","DOI":"10.1016\/j.phrs.2015.03.010"},{"key":"2023100409531721958_j_revneuro-2022-0093_ref_046","doi-asserted-by":"crossref","unstructured":"Greenberg, S.M., Vernooij, M.W., Cordonnier, C., Viswanathan, A., Al-Shahi Salman, R., Warach, S., Launer, L.J., Van Buchem, M.A., and Breteler, M.M. (2009). Cerebral microbleeds: a guide to detection and interpretation. Lancet Neurol. 8: 165\u2013174, https:\/\/doi.org\/10.1016\/s1474-4422(09)70013-4.","DOI":"10.1016\/S1474-4422(09)70013-4"},{"key":"2023100409531721958_j_revneuro-2022-0093_ref_047","doi-asserted-by":"crossref","unstructured":"Hasegawa, S., Goto, S., Tsuji, H., Okuno, T., Asahara, T., Nomoto, K., Shibata, A., Fujisawa, Y., Minato, T., Okamoto, A., et al.. (2015). Intestinal dysbiosis and lowered serum lipopolysaccharide-binding protein in Parkinson\u2019s Disease. PLoS One 10: e0142164, https:\/\/doi.org\/10.1371\/journal.pone.0142164.","DOI":"10.1371\/journal.pone.0142164"},{"key":"2023100409531721958_j_revneuro-2022-0093_ref_048","doi-asserted-by":"crossref","unstructured":"Heras-Sandoval, D., P\u00e9rez-Rojas, J.M., Hern\u00e1ndez-Dami\u00e1n, J., and Pedraza-Chaverri, J. (2014). The role of PI3K\/AKT\/mTOR pathway in the modulation of autophagy and the clearance of protein aggregates in neurodegeneration. Cell Signal 26: 2694\u20132701, https:\/\/doi.org\/10.1016\/j.cellsig.2014.08.019.","DOI":"10.1016\/j.cellsig.2014.08.019"},{"key":"2023100409531721958_j_revneuro-2022-0093_ref_049","doi-asserted-by":"crossref","unstructured":"Hernandez-Baltazar, D., Mendoza-Garrido, M.E., and Martinez-Fong, D. (2013). Activation of GSK-3\u03b2 and caspase-3 occurs in Nigral dopamine neurons during the development of apoptosis activated by a striatal injection of 6-hydroxydopamine. PLoS One 8: e70951, https:\/\/doi.org\/10.1371\/journal.pone.0070951.","DOI":"10.1371\/journal.pone.0070951"},{"key":"2023100409531721958_j_revneuro-2022-0093_ref_050","doi-asserted-by":"crossref","unstructured":"Hirsch, E.C. and Hunot, S. (2009). Neuroinflammation in Parkinson\u2019s disease: a target for neuroprotection. Lancet Neurol. 8: 382\u2013397, https:\/\/doi.org\/10.1016\/s1474-4422(09)70062-6.","DOI":"10.1016\/S1474-4422(09)70062-6"},{"key":"2023100409531721958_j_revneuro-2022-0093_ref_051","doi-asserted-by":"crossref","unstructured":"Ho, P.W., Liu, H.F., Ho, J.W., Zhang, W.Y., Chu, A.C., Kwok, K.H., Ge, X., Chan, K.H., Ramsden, D.B., and Ho, S.L. (2010). Mitochondrial uncoupling protein-2 (UCP2) mediates leptin protection against MPP+ toxicity in neuronal cells. Neurotox. Res. 17: 332\u2013343, https:\/\/doi.org\/10.1007\/s12640-009-9109-y.","DOI":"10.1007\/s12640-009-9109-y"},{"key":"2023100409531721958_j_revneuro-2022-0093_ref_052","doi-asserted-by":"crossref","unstructured":"Horvath, I. and Wittung-Stafshede, P. (2016). Cross-talk between amyloidogenic proteins in type-2 diabetes and Parkinson\u2019s disease. Proc. Natl. Acad. Sci. U.S.A. 113: 12473\u201312477, https:\/\/doi.org\/10.1073\/pnas.1610371113.","DOI":"10.1073\/pnas.1610371113"},{"key":"2023100409531721958_j_revneuro-2022-0093_ref_053","doi-asserted-by":"crossref","unstructured":"Hotamisligil, G.S. (2017). Inflammation, metaflammation and immunometabolic disorders. Nature 542: 177\u2013185, https:\/\/doi.org\/10.1038\/nature21363.","DOI":"10.1038\/nature21363"},{"key":"2023100409531721958_j_revneuro-2022-0093_ref_054","doi-asserted-by":"crossref","unstructured":"Hou, L., Li, Q., Jiang, L., Qiu, H., Geng, C., Hong, J.S., Li, H., and Wang, Q. (2018). Hypertension and diagnosis of Parkinson\u2019s disease: a\u00a0meta-analysis of cohort studies. Front. Neurol. 9: 162, https:\/\/doi.org\/10.3389\/fneur.2018.00162.","DOI":"10.3389\/fneur.2018.00162"},{"key":"2023100409531721958_j_revneuro-2022-0093_ref_055","doi-asserted-by":"crossref","unstructured":"Hu, G., Jousilahti, P., Bidel, S., Antikainen, R., and Tuomilehto, J. (2007). Type 2 diabetes and the risk of Parkinson\u2019s disease. Diabetes Care 30: 842\u2013847, https:\/\/doi.org\/10.2337\/dc06-2011.","DOI":"10.2337\/dc06-2011"},{"key":"2023100409531721958_j_revneuro-2022-0093_ref_056","doi-asserted-by":"crossref","unstructured":"Hu, G., Jousilahti, P., Nissinen, A., Antikainen, R., Kivipelto, M., and Tuomilehto, J. (2006). Body mass index and the risk of Parkinson disease. Neurology 67: 1955\u20131959, https:\/\/doi.org\/10.1212\/01.wnl.0000247052.18422.e5.","DOI":"10.1212\/01.wnl.0000247052.18422.e5"},{"key":"2023100409531721958_j_revneuro-2022-0093_ref_057","doi-asserted-by":"crossref","unstructured":"Huang, X., Abbott, R.D., Petrovitch, H., Mailman, R.B., and Ross, G.W. (2008). Low LDL cholesterol and increased risk of Parkinson\u2019s disease: prospective results from Honolulu-Asia Aging Study. Mov. Disord. 23: 1013\u20131018, https:\/\/doi.org\/10.1002\/mds.22013.","DOI":"10.1002\/mds.22013"},{"key":"2023100409531721958_j_revneuro-2022-0093_ref_058","doi-asserted-by":"crossref","unstructured":"Huang, X., Alonso, A., Guo, X., Umbach, D.M., Lichtenstein, M.L., Ballantyne, C.M., Mailman, R.B., Mosley, T.H., and Chen, H. (2015). Statins, plasma cholesterol, and risk of Parkinson\u2019s disease: a prospective study. Mov. Disord. 30: 552\u2013559, https:\/\/doi.org\/10.1002\/mds.26152.","DOI":"10.1002\/mds.26152"},{"key":"2023100409531721958_j_revneuro-2022-0093_ref_059","doi-asserted-by":"crossref","unstructured":"Huang, X., Chen, H., Miller, W.C., Mailman, R.B., Woodard, J.L., Chen, P.C., Xiang, D., Murrow, R.W., Wang, Y.Z., and Poole, C. (2007). Lower low-density lipoprotein cholesterol levels are associated with Parkinson\u2019s disease. Mov. Disord. 22: 377\u2013381, https:\/\/doi.org\/10.1002\/mds.21290.","DOI":"10.1002\/mds.21290"},{"key":"2023100409531721958_j_revneuro-2022-0093_ref_060","doi-asserted-by":"crossref","unstructured":"Hughes, D., Judge, C., Murphy, R., Loughlin, E., Costello, M., Whiteley, W., Bosch, J., O\u2019Donnell, M.J., and Canavan, M. (2020). Association of Blood pressure lowering with incident dementia or cognitive impairment: a systematic review and meta-analysis. J.\u00a0Am. Med. Assoc. 323: 1934\u20131944, https:\/\/doi.org\/10.1001\/jama.2020.4249.","DOI":"10.1001\/jama.2020.4249"},{"key":"2023100409531721958_j_revneuro-2022-0093_ref_061","doi-asserted-by":"crossref","unstructured":"Hussain, S., Singh, A., Baxi, H., Taylor, B., Burgess, J., and Antony, B. (2020). Thiazolidinedione use is associated with reduced risk of Parkinson\u2019s disease in patients with diabetes: a meta-analysis of real-world evidence. Neurol. Sci. 41: 3697\u20133703, https:\/\/doi.org\/10.1007\/s10072-020-04494-3.","DOI":"10.1007\/s10072-020-04494-3"},{"key":"2023100409531721958_j_revneuro-2022-0093_ref_063","doi-asserted-by":"crossref","unstructured":"Jamwal, S., Blackburn, J.K., and Elsworth, J.D. (2021). PPAR\u03b3\/PGC1\u03b1 signaling as a potential therapeutic target for mitochondrial biogenesis in neurodegenerative disorders. Pharmacol. Ther. 219: 107705, https:\/\/doi.org\/10.1016\/j.pharmthera.2020.107705.","DOI":"10.1016\/j.pharmthera.2020.107705"},{"key":"2023100409531721958_j_revneuro-2022-0093_ref_064","doi-asserted-by":"crossref","unstructured":"Janssen-Heininger, Y.M., Mossman, B.T., Heintz, N.H., Forman, H.J., Kalyanaraman, B., Finkel, T., Stamler, J.S., Rhee, S.G., and van der Vliet, A. (2008). Redox-based regulation of signal transduction: principles, pitfalls, and promises. Free Radic. Biol. Med. 45: 1\u201317, https:\/\/doi.org\/10.1016\/j.freeradbiomed.2008.03.011.","DOI":"10.1016\/j.freeradbiomed.2008.03.011"},{"key":"2023100409531721958_j_revneuro-2022-0093_ref_065","doi-asserted-by":"crossref","unstructured":"Jellinger, K.A. (2003). Prevalence of cerebrovascular lesions in Parkinson\u2019s disease. A postmortem study. Acta Neuropathol. 105: 415\u2013419, https:\/\/doi.org\/10.1007\/s00401-003-0676-3.","DOI":"10.1007\/s00401-003-0676-3"},{"key":"2023100409531721958_j_revneuro-2022-0093_ref_066","doi-asserted-by":"crossref","unstructured":"Jeong, S.H., Lee, H.S., Chung, S.J., Yoo, H.S., Jung, J.H., Baik, K., Baik, J.S., Sohn, Y.H., and Lee, P.H. (2022). Association of cholesterol level with dopamine loss and motor deficits in Parkinson disease: a cross-sectional study. Eur. J.\u00a0Neurol. 1\u20139, https:\/\/doi.org\/10.1111\/ene.14152.","DOI":"10.1111\/ene.15592"},{"key":"2023100409531721958_j_revneuro-2022-0093_ref_067","doi-asserted-by":"crossref","unstructured":"Jeong, S.H., Lee, H.S., Chung, S.J., Yoo, H.S., Jung, J.H., Baik, K., Lee, Y.H., Sohn, Y.H., and Lee, P.H. (2021). Effects of statins on dopamine loss and prognosis in Parkinson\u2019s disease. Brain 144: 3191\u20133200, https:\/\/doi.org\/10.1093\/brain\/awab292.","DOI":"10.1093\/brain\/awab292"},{"key":"2023100409531721958_j_revneuro-2022-0093_ref_068","doi-asserted-by":"crossref","unstructured":"Jiang, W., Zou, W., Hu, M., Tian, Q., Xiao, F., Li, M., Zhang, P., Chen, Y.J., and Jiang, J.M. (2022). Hydrogen sulphide attenuates neuronal apoptosis of substantia nigra by re-establishing autophagic flux via promoting leptin signalling in a 6-hydroxydopamine rat model of Parkinson\u2019s disease. Clin. Exp. Pharmacol. Physiol. 49: 122\u2013133, https:\/\/doi.org\/10.1111\/1440-1681.13587.","DOI":"10.1111\/1440-1681.13587"},{"key":"2023100409531721958_j_revneuro-2022-0093_ref_069","doi-asserted-by":"crossref","unstructured":"Johnson, J.B., Summer, W., Cutler, R.G., Martin, B., Hyun, D.H., Dixit, V.D., Pearson, M., Nassar, M., Telljohann, R., Maudsley, S., et al.. (2007). Alternate day calorie restriction improves clinical findings and reduces markers of oxidative stress and inflammation in overweight adults with moderate asthma. Free Radic. Biol. Med. 42: 665\u2013674, https:\/\/doi.org\/10.1016\/j.freeradbiomed.2006.12.005.","DOI":"10.1016\/j.freeradbiomed.2007.06.008"},{"key":"2023100409531721958_j_revneuro-2022-0093_ref_070","doi-asserted-by":"crossref","unstructured":"Kahn, S.E., Hull, R.L., and Utzschneider, K.M. (2006). Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 444: 840\u2013846, https:\/\/doi.org\/10.1038\/nature05482.","DOI":"10.1038\/nature05482"},{"key":"2023100409531721958_j_revneuro-2022-0093_ref_071","doi-asserted-by":"crossref","unstructured":"Kanemaki, T., Kitade, H., Kaibori, M., Sakitani, K., Hiramatsu, Y., Kamiyama, Y., Ito, S., and Okumura, T. (1998). Interleukin 1\u03b2 and interleukin 6, but not tumor necrosis factor alpha, inhibit insulin-stimulated glycogen synthesis in rat hepatocytes. Hepatology 27: 1296\u20131303, https:\/\/doi.org\/10.1002\/hep.510270515.","DOI":"10.1002\/hep.510270515"},{"key":"2023100409531721958_j_revneuro-2022-0093_ref_072","doi-asserted-by":"crossref","unstructured":"Katila, N., Bhurtel, S., Shadfar, S., Srivastav, S., Neupane, S., Ojha, U., Jeong, G.S., and Choi, D.Y. (2017). Metformin lowers \u03b1-synuclein phosphorylation and upregulates neurotrophic factor in the MPTP mouse model of Parkinson\u2019s disease. Neuropharmacology 125: 396\u2013407, https:\/\/doi.org\/10.1016\/j.neuropharm.2017.08.015.","DOI":"10.1016\/j.neuropharm.2017.08.015"},{"key":"2023100409531721958_j_revneuro-2022-0093_ref_073","doi-asserted-by":"crossref","unstructured":"Keshavarzian, A., Green, S.J., Engen, P.A., Voigt, R.M., Naqib, A., Forsyth, C.B., Mutlu, E., and Shannon, K.M. (2015). Colonic bacterial composition in Parkinson\u2019s disease. Mov. Disord. 30: 1351\u20131360, https:\/\/doi.org\/10.1002\/mds.26307.","DOI":"10.1002\/mds.26307"},{"key":"2023100409531721958_j_revneuro-2022-0093_ref_074","doi-asserted-by":"crossref","unstructured":"Kim, S.R., Ries, V., Cheng, H.C., Kareva, T., Oo, T.F., Yu, W.H., Duff, K., Kholodilov, N., and Burke, R.E. (2011). Age and \u03b1-synuclein expression interact to reveal a dependence of dopaminergic axons on endogenous Akt\/PKB signaling. Neurobiol. Dis. 44: 215\u2013222, https:\/\/doi.org\/10.1016\/j.nbd.2011.07.003.","DOI":"10.1016\/j.nbd.2011.07.003"},{"key":"2023100409531721958_j_revneuro-2022-0093_ref_075","doi-asserted-by":"crossref","unstructured":"Kizza, J., Lewington, S., Mappin-Kasirer, B., Turnbull, I., Guo, Y., Bian, Z., Chen, Y., Yang, L., Chen, Z., Clarke, R., et al.. (2019). Cardiovascular risk factors and Parkinson\u2019s disease in 500, 000 Chinese adults. Ann. Clin. Transl. Neurol. 6: 624\u2013632, https:\/\/doi.org\/10.1002\/acn3.732.","DOI":"10.1002\/acn3.732"},{"key":"2023100409531721958_j_revneuro-2022-0093_ref_077","doi-asserted-by":"crossref","unstructured":"Larsen, N., Vogensen, F.K., van den Berg, F.W., Nielsen, D.S., Andreasen, A.S., Pedersen, B.K., Al-Soud, W.A., S\u00f8rensen, S.J., Hansen, L.H., and Jakobsen, M. (2010). Gut microbiota in human adults with type 2 diabetes differs from non-diabetic adults. PLoS One 5: e9085, https:\/\/doi.org\/10.1371\/journal.pone.0009085.","DOI":"10.1371\/journal.pone.0009085"},{"key":"2023100409531721958_j_revneuro-2022-0093_ref_078","doi-asserted-by":"crossref","unstructured":"Lee, Y.C., Lin, C.H., Wu, R.M., Lin, J.W., Chang, C.H., and Lai, M.S. (2014). Antihypertensive agents and risk of Parkinson\u2019s disease: a nationwide cohort study. PLoS One 9: e98961, https:\/\/doi.org\/10.1371\/journal.pone.0098961.","DOI":"10.1371\/journal.pone.0098961"},{"key":"2023100409531721958_j_revneuro-2022-0093_ref_079","doi-asserted-by":"crossref","unstructured":"Lim, L., Jackson-Lewis, V., Wong, L.C., Shui, G.H., Goh, A.X., Kesavapany, S., Jenner, A.M., Fivaz, M., Przedborski, S., and Wenk, M.R. (2012). Lanosterol induces mitochondrial uncoupling and protects dopaminergic neurons from cell death in a model for Parkinson\u2019s disease. Cell Death Differ. 19: 416\u2013427, https:\/\/doi.org\/10.1038\/cdd.2011.105.","DOI":"10.1038\/cdd.2011.105"},{"key":"2023100409531721958_j_revneuro-2022-0093_ref_080","doi-asserted-by":"crossref","unstructured":"Liu, L., Zhang, K., Sandoval, H., Yamamoto, S., Jaiswal, M., Sanz, E., Li, Z., Hui, J., Graham, B.H., Quintana, A., et al.. (2015). Glial lipid droplets and ROS induced by mitochondrial defects promote neurodegeneration. Cell 160: 177\u2013190, https:\/\/doi.org\/10.1016\/j.cell.2014.12.019.","DOI":"10.1016\/j.cell.2014.12.019"},{"key":"2023100409531721958_j_revneuro-2022-0093_ref_081","doi-asserted-by":"crossref","unstructured":"Liu, M., Bachstetter, A.D., Cass, W.A., Lifshitz, J., and Bing, G. (2017). Pioglitazone attenuates neuroinflammation and promotes dopaminergic neuronal survival in the nigrostriatal system of rats after diffuse brain injury. J.\u00a0Neurotrauma 34: 414\u2013422, https:\/\/doi.org\/10.1089\/neu.2015.4361.","DOI":"10.1089\/neu.2015.4361"},{"key":"2023100409531721958_j_revneuro-2022-0093_ref_082","doi-asserted-by":"crossref","unstructured":"Liu, Q., Trotter, J., Zhang, J., Peters, M.M., Cheng, H., Bao, J., Han, X., Weeber, E.J., and Bu, G. (2010). Neuronal LRP1 knockout in adult mice leads to impaired brain lipid metabolism and progressive, age-dependent synapse loss and neurodegeneration. J.\u00a0Neurosci. 30: 17068\u201317078, https:\/\/doi.org\/10.1523\/jneurosci.4067-10.2010.","DOI":"10.1523\/JNEUROSCI.4067-10.2010"},{"key":"2023100409531721958_j_revneuro-2022-0093_ref_083","doi-asserted-by":"crossref","unstructured":"Liu, W., Jalewa, J., Sharma, M., Li, G., Li, L., and H\u00f6lscher, C. (2015). Neuroprotective effects of lixisenatide and liraglutide in the 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine mouse model of Parkinson\u2019s disease. Neuroscience 303: 42\u201350, https:\/\/doi.org\/10.1016\/j.neuroscience.2015.06.054.","DOI":"10.1016\/j.neuroscience.2015.06.054"},{"key":"2023100409531721958_j_revneuro-2022-0093_ref_084","doi-asserted-by":"crossref","unstructured":"Logica, T., Riviere, S., Holubiec, M.I., Castilla, R., Barreto, G.E., and Capani, F. (2016). Metabolic changes following perinatal asphyxia: role of astrocytes and their interaction with neurons. Front. Aging Neurosci. 8: 116, https:\/\/doi.org\/10.3389\/fnagi.2016.00116.","DOI":"10.3389\/fnagi.2016.00116"},{"key":"2023100409531721958_j_revneuro-2022-0093_ref_085","doi-asserted-by":"crossref","unstructured":"Lu, J., Park, C.S., Lee, S.K., Shin, D.W., and Kang, J.H. (2006). Leptin inhibits 1-methyl-4-phenylpyridinium-induced cell death in SH-SY5Y cells. Neurosci. Lett. 407: 240\u2013243, https:\/\/doi.org\/10.1016\/j.neulet.2006.08.053.","DOI":"10.1016\/j.neulet.2006.08.053"},{"key":"2023100409531721958_j_revneuro-2022-0093_ref_086","doi-asserted-by":"crossref","unstructured":"Machado, M., Bassani, T.B., C\u00f3ppola-Segovia, V., Moura, E., Zanata, S.M., Andreatini, R., and Vital, M. (2019). PPAR-\u03b3 agonist pioglitazone reduces microglial proliferation and NF-\u03baB activation in the substantia nigra in the 6-hydroxydopamine model of Parkinson\u2019s disease. Pharmacol. Rep. 71: 556\u2013564, https:\/\/doi.org\/10.1016\/j.pharep.2018.11.005.","DOI":"10.1016\/j.pharep.2018.11.005"},{"key":"2023100409531721958_j_revneuro-2022-0093_ref_087","doi-asserted-by":"crossref","unstructured":"Malagelada, C., Jin, Z.H., and Greene, L.A. (2008). RTP801 is induced in Parkinson\u2019s disease and mediates neuron death by inhibiting Akt phosphorylation\/activation. J.\u00a0Neurosci. 28: 14363\u201314371, https:\/\/doi.org\/10.1523\/jneurosci.3928-08.2008.","DOI":"10.1523\/JNEUROSCI.3928-08.2008"},{"key":"2023100409531721958_j_revneuro-2022-0093_ref_088","doi-asserted-by":"crossref","unstructured":"Mallet, D., Dufourd, T., Decourt, M., Carcenac, C., Boss\u00f9, P., Verlin, L., Fernagut, P.O., Benoit-Marand, M., Spalletta, G., Barbier, E.L., et al.. (2022a). A metabolic biomarker predicts Parkinson\u2019s disease at the early stages in patients and animal models. J.\u00a0Clin. Invest. 132: 146400, https:\/\/doi.org\/10.1172\/jci146400.","DOI":"10.1172\/JCI146400"},{"key":"2023100409531721958_j_revneuro-2022-0093_ref_089","doi-asserted-by":"crossref","unstructured":"Mallet, D., Goutaudier, R., Barbier, E.L., Carnicella, S., Colca, J.R., Fauvelle, F., and Boulet, S. (2022b). Re-routing metabolism by the mitochondrial pyruvate carrier inhibitor MSDC-0160 attenuates neurodegeneration in a rat model of Parkinson\u2019s disease. Mol. Neurobiol. 59: 6170\u20136182, https:\/\/doi.org\/10.1007\/s12035-022-02962-9.","DOI":"10.1007\/s12035-022-02962-9"},{"key":"2023100409531721958_j_revneuro-2022-0093_ref_090","doi-asserted-by":"crossref","unstructured":"Martin, B., Mattson, M.P., and Maudsley, S. (2006). Caloric restriction and intermittent fasting: two potential diets for successful brain aging. Ageing Res. Rev. 5: 332\u2013353, https:\/\/doi.org\/10.1016\/j.arr.2006.04.002.","DOI":"10.1016\/j.arr.2006.04.002"},{"key":"2023100409531721958_j_revneuro-2022-0093_ref_091","doi-asserted-by":"crossref","unstructured":"Martin-Jim\u00e9nez, C.A., Garc\u00eda-Vega, \u00c1., Cabezas, R., Aliev, G., Echeverria, V., Gonz\u00e1lez, J., and Barreto, G.E. (2017). Astrocytes and endoplasmic reticulum stress: a bridge between obesity and neurodegenerative diseases. Prog. Neurobiol. 158: 45\u201368, https:\/\/doi.org\/10.1016\/j.pneurobio.2017.08.001.","DOI":"10.1016\/j.pneurobio.2017.08.001"},{"key":"2023100409531721958_j_revneuro-2022-0093_ref_092","doi-asserted-by":"crossref","unstructured":"Mattson, M.P., Pedersen, W.A., Duan, W., Culmsee, C., and Camandola, S. (1999). Cellular and molecular mechanisms underlying perturbed energy metabolism and neuronal degeneration in Alzheimer\u2019s and Parkinson\u2019s diseases. Ann. N. Y. Acad. Sci. 893: 154\u2013175, https:\/\/doi.org\/10.1111\/j.1749-6632.1999.tb07824.x.","DOI":"10.1111\/j.1749-6632.1999.tb07824.x"},{"key":"2023100409531721958_j_revneuro-2022-0093_ref_093","doi-asserted-by":"crossref","unstructured":"Miyake, Y., Tanaka, K., Fukushima, W., Sasaki, S., Kiyohara, C., Tsuboi, Y., Yamada, T., Oeda, T., Miki, T., Kawamura, N., et al.. (2010). Case-control study of risk of Parkinson\u2019s disease in relation to hypertension, hypercholesterolemia, and diabetes in Japan. J.\u00a0Neurol. Sci. 293: 82\u201386, https:\/\/doi.org\/10.1016\/j.jns.2010.03.002.","DOI":"10.1016\/j.jns.2010.03.002"},{"key":"2023100409531721958_j_revneuro-2022-0093_ref_094","doi-asserted-by":"crossref","unstructured":"Mlinar, B. and Marc, J. (2011). New insights into adipose tissue dysfunction in insulin resistance. Clin. Chem. Lab. Med. 49: 1925\u20131935, https:\/\/doi.org\/10.1515\/cclm.2011.697.","DOI":"10.1515\/CCLM.2011.697"},{"key":"2023100409531721958_j_revneuro-2022-0093_ref_095","doi-asserted-by":"crossref","unstructured":"Moroo, I., Yamada, T., Makino, H., Tooyama, I., McGeer, P.L., McGeer, E.G., and Hirayama, K. (1994). Loss of insulin receptor immunoreactivity from the substantia nigra pars compacta neurons in Parkinson\u2019s disease. Acta Neuropathol. 87: 343\u2013348, https:\/\/doi.org\/10.1007\/bf00313602.","DOI":"10.1007\/BF00313602"},{"key":"2023100409531721958_j_revneuro-2022-0093_ref_096","doi-asserted-by":"crossref","unstructured":"Mottillo, S., Filion, K.B., Genest, J., Joseph, L., Pilote, L., Poirier, P., Rinfret, S., Schiffrin, E.L., and Eisenberg, M.J. (2010). The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. J.\u00a0Am. Coll. Cardiol. 56: 1113\u20131132, https:\/\/doi.org\/10.1016\/j.jacc.2010.05.034.","DOI":"10.1016\/j.jacc.2010.05.034"},{"key":"2023100409531721958_j_revneuro-2022-0093_ref_097","doi-asserted-by":"crossref","unstructured":"Naderali, E.K., Ratcliffe, S.H., and Dale, M.C. (2009). Obesity and Alzheimer\u2019s disease: a link between body weight and cognitive function in old age. Am. J.\u00a0Alzheimer\u2019s Dis. Other Demen. 24: 445\u2013449, https:\/\/doi.org\/10.1177\/1533317509348208.","DOI":"10.1177\/1533317509348208"},{"key":"2023100409531721958_j_revneuro-2022-0093_ref_098","doi-asserted-by":"crossref","unstructured":"Nagatsu, T., Mogi, M., Ichinose, H., and Togari, A. (2000). Changes in cytokines and neurotrophins in Parkinson\u2019s disease. J.\u00a0Neural. Transm. 277\u2013290.","DOI":"10.1007\/978-3-7091-6301-6_19"},{"key":"2023100409531721958_j_revneuro-2022-0093_ref_099","doi-asserted-by":"crossref","unstructured":"Nam, G.E., Kim, S.M., Han, K., Kim, N.H., Chung, H.S., Kim, J.W., Han, B., Cho, S.J., Yu, J.H., Park, Y.G., et al.. (2018). Metabolic syndrome and risk of Parkinson disease: a nationwide cohort study. PLoS Med. 15: e1002640, https:\/\/doi.org\/10.1371\/journal.pmed.1002640.","DOI":"10.1371\/journal.pmed.1002640"},{"key":"2023100409531721958_j_revneuro-2022-0093_ref_100","doi-asserted-by":"crossref","unstructured":"Nassar, N.N., Al-Shorbagy, M.Y., Arab, H.H., and Abdallah, D.M. (2015). Saxagliptin: a novel antiparkinsonian approach. Neuropharmacology 89: 308\u2013317, https:\/\/doi.org\/10.1016\/j.neuropharm.2014.10.007.","DOI":"10.1016\/j.neuropharm.2014.10.007"},{"key":"2023100409531721958_j_revneuro-2022-0093_ref_101","doi-asserted-by":"crossref","unstructured":"Ng, Y.F., Ng, E., Lim, E.W., Prakash, K.M., Tan, L., and Tan, E.K. (2021). Case-control study of hypertension and Parkinson\u2019s disease. NPJ Parkinson\u2019s Dis. 7: 63, https:\/\/doi.org\/10.1038\/s41531-021-00202-w.","DOI":"10.1038\/s41531-021-00202-w"},{"key":"2023100409531721958_j_revneuro-2022-0093_ref_001","doi-asserted-by":"crossref","unstructured":"NINDS Exploratory Trials in Parkinson Disease (NET-PD) FS-ZONE Investigators (2015). Pioglitazone in early Parkinson\u2019s disease: a phase 2, multicentre, double-blind, randomised trial. Lancet Neurol. 14: 795\u2013803.","DOI":"10.1016\/S1474-4422(15)00144-1"},{"key":"2023100409531721958_j_revneuro-2022-0093_ref_102","doi-asserted-by":"crossref","unstructured":"Nishimura, M., Izumiya, Y., Higuchi, A., Shibata, R., Qiu, J., Kudo, C., Shin, H.K., Moskowitz, M.A., and Ouchi, N. (2008). Adiponectin prevents cerebral ischemic injury through endothelial nitric oxide synthase dependent mechanisms. Circulation 117: 216\u2013223, https:\/\/doi.org\/10.1161\/circulationaha.107.725044.","DOI":"10.1161\/CIRCULATIONAHA.107.725044"},{"key":"2023100409531721958_j_revneuro-2022-0093_ref_103","doi-asserted-by":"crossref","unstructured":"Paganini-Hill, A. (2001). Risk factors for Parkinson\u2019s disease: the leisure world cohort study. Neuroepidemiology 20: 118\u2013124, https:\/\/doi.org\/10.1159\/000054770.","DOI":"10.1159\/000054770"},{"key":"2023100409531721958_j_revneuro-2022-0093_ref_104","doi-asserted-by":"crossref","unstructured":"Paolisso, G., Tagliamonte, M.R., Rizzo, M.R., and Giugliano, D. (1999). Advancing age and insulin resistance: new facts about an ancient history. Eur. J.\u00a0Clin. Invest. 29: 758\u2013769, https:\/\/doi.org\/10.1046\/j.1365-2362.1999.00522.x.","DOI":"10.1046\/j.1365-2362.1999.00522.x"},{"key":"2023100409531721958_j_revneuro-2022-0093_ref_105","doi-asserted-by":"crossref","unstructured":"Pekny, M., Wilhelmsson, U., and Pekna, M. (2014). The dual role of astrocyte activation and reactive gliosis. Neurosci. Lett. 565: 30\u201338, https:\/\/doi.org\/10.1016\/j.neulet.2013.12.071.","DOI":"10.1016\/j.neulet.2013.12.071"},{"key":"2023100409531721958_j_revneuro-2022-0093_ref_106","doi-asserted-by":"crossref","unstructured":"Peng, Z., Zhou, R., Liu, D., Cui, M., Yu, K., Yang, H., Li, L., Liu, J., Chen, Y., Hong, W., et al.. (2021). Association between metabolic syndrome and mild parkinsonian signs progression in the elderly. Front. Aging Neurosci. 13: 722836, https:\/\/doi.org\/10.3389\/fnagi.2021.722836.","DOI":"10.3389\/fnagi.2021.722836"},{"key":"2023100409531721958_j_revneuro-2022-0093_ref_107","doi-asserted-by":"crossref","unstructured":"Perl, D.P., Olanow, C.W., and Calne, D. (1998). Alzheimer\u2019s disease and Parkinson\u2019s disease: distinct entities or extremes of a spectrum of neurodegeneration. Ann. Neurol. 44: S19\u2013S31, https:\/\/doi.org\/10.1002\/ana.410440705.","DOI":"10.1002\/ana.410440705"},{"key":"2023100409531721958_j_revneuro-2022-0093_ref_108","doi-asserted-by":"crossref","unstructured":"Perry, V.H. (2004). The influence of systemic inflammation on inflammation in the brain: implications for chronic neurodegenerative disease. Brain Behav. Immun. 18: 407\u2013413, https:\/\/doi.org\/10.1016\/j.bbi.2004.01.004.","DOI":"10.1016\/j.bbi.2004.01.004"},{"key":"2023100409531721958_j_revneuro-2022-0093_ref_109","doi-asserted-by":"crossref","unstructured":"Petersen, K.F., Dufour, S., Savage, D.B., Bilz, S., Solomon, G., Yonemitsu, S., Cline, G.W., Befroy, D., Zemany, L., Kahn, B.B., et al.. (2007). The role of skeletal muscle insulin resistance in the pathogenesis of the metabolic syndrome. Proc. Natl. Acad. Sci. U.S.A. 104: 12587\u201312594, https:\/\/doi.org\/10.1073\/pnas.0705408104.","DOI":"10.1073\/pnas.0705408104"},{"key":"2023100409531721958_j_revneuro-2022-0093_ref_110","doi-asserted-by":"crossref","unstructured":"Pires, P.W., Dams Ramos, C.M., Matin, N., and Dorrance, A.M. (2013). The effects of hypertension on the cerebral circulation. Am. J.\u00a0Physiol. Heart Circ. Physiol. 304: H1598\u2013H1614, https:\/\/doi.org\/10.1152\/ajpheart.00490.2012.","DOI":"10.1152\/ajpheart.00490.2012"},{"key":"2023100409531721958_j_revneuro-2022-0093_ref_111","doi-asserted-by":"crossref","unstructured":"Qiu, C., Hu, G., Kivipelto, M., Laatikainen, T., Antikainen, R., Fratiglioni, L., Jousilahti, P., and Tuomilehto, J. (2011). Association of blood pressure and hypertension with the risk of Parkinson disease: the National FINRISK Study. Hypertension 57: 1094\u20131100, https:\/\/doi.org\/10.1161\/hypertensionaha.111.171249.","DOI":"10.1161\/HYPERTENSIONAHA.111.171249"},{"key":"2023100409531721958_j_revneuro-2022-0093_ref_112","doi-asserted-by":"crossref","unstructured":"Quinn, L.P., Crook, B., Hows, M.E., Vidgeon-Hart, M., Chapman, H., Upton, N., Medhurst, A.D., and Virley, D.J. (2008). The PPARgamma agonist pioglitazone is effective in the MPTP mouse model of Parkinson\u2019s disease through inhibition of monoamine oxidase B. Br. J.\u00a0Pharmacol. 154: 226\u2013233, https:\/\/doi.org\/10.1038\/bjp.2008.78.","DOI":"10.1038\/bjp.2008.78"},{"key":"2023100409531721958_j_revneuro-2022-0093_ref_113","doi-asserted-by":"crossref","unstructured":"Rantham Prabhakara, J.P., Feist, G., Thomasson, S., Thompson, A., Schommer, E., and Ghribi, O. (2008). Differential effects of 24-hydroxycholesterol and 27-hydroxycholesterol on tyrosine hydroxylase and alpha-synuclein in human neuroblastoma SH-SY5Y cells. J.\u00a0Neurochem. 107: 1722\u20131729, https:\/\/doi.org\/10.1111\/j.1471-4159.2008.05736.x.","DOI":"10.1111\/j.1471-4159.2008.05736.x"},{"key":"2023100409531721958_j_revneuro-2022-0093_ref_114","doi-asserted-by":"crossref","unstructured":"Ridker, P.M., Hennekens, C.H., Buring, J.E., and Rifai, N. (2000). C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N. Engl. J.\u00a0Med. 342: 836\u2013843, https:\/\/doi.org\/10.1056\/nejm200003233421202.","DOI":"10.1056\/NEJM200003233421202"},{"key":"2023100409531721958_j_revneuro-2022-0093_ref_115","doi-asserted-by":"crossref","unstructured":"Rius-P\u00e9rez, S., Torres-Cuevas, I., Mill\u00e1n, I., Ortega, \u00c1.L., and P\u00e9rez, S. (2020). PGC-1\u03b1, Inflammation, and oxidative stress: an integrative view in metabolism. Oxid. Med. Cell. Longev. 2020: 1452696, https:\/\/doi.org\/10.1155\/2020\/1452696.","DOI":"10.1155\/2020\/1452696"},{"key":"2023100409531721958_j_revneuro-2022-0093_ref_116","doi-asserted-by":"crossref","unstructured":"Roh, J.H., Lee, S., and Yoon, J.H. (2021). Metabolic syndrome and Parkinson\u2019s disease incidence: a nationwide study using propensity score matching. Metab. Syndr. Relat. Disord. 19: 1\u20137, https:\/\/doi.org\/10.1089\/met.2020.0060.","DOI":"10.1089\/met.2020.0060"},{"key":"2023100409531721958_j_revneuro-2022-0093_ref_117","doi-asserted-by":"crossref","unstructured":"Rolo, A.P., Teodoro, J.S., and Palmeira, C.M. (2012). Role of oxidative stress in the pathogenesis of nonalcoholic steatohepatitis. Free Radic. Biol. Med. 52: 59\u201369, https:\/\/doi.org\/10.1016\/j.freeradbiomed.2011.10.003.","DOI":"10.1016\/j.freeradbiomed.2011.10.003"},{"key":"2023100409531721958_j_revneuro-2022-0093_ref_118","doi-asserted-by":"crossref","unstructured":"Romeo, G.R., Lee, J., and Shoelson, S.E. (2012). Metabolic syndrome, insulin resistance, and roles of inflammation\u2013mechanisms and therapeutic targets. Arterioscler. Thromb. Vasc. Biol. 32: 1771\u20131776, https:\/\/doi.org\/10.1161\/atvbaha.111.241869.","DOI":"10.1161\/ATVBAHA.111.241869"},{"key":"2023100409531721958_j_revneuro-2022-0093_ref_119","doi-asserted-by":"crossref","unstructured":"Ryu, Y.K., Go, J., Park, H.Y., Choi, Y.K., Seo, Y.J., Choi, J.H., Rhee, M., Lee, T.G., Lee, C.H., and Kim, K.S. (2020). Metformin regulates astrocyte reactivity in Parkinson\u2019s disease and normal aging. Neuropharmacology 175: 108173, https:\/\/doi.org\/10.1016\/j.neuropharm.2020.108173.","DOI":"10.1016\/j.neuropharm.2020.108173"},{"key":"2023100409531721958_j_revneuro-2022-0093_ref_120","doi-asserted-by":"crossref","unstructured":"Ryu, Y.K., Park, H.Y., Go, J., Choi, D.H., Kim, Y.H., Hwang, J.H., Noh, J.R., Lee, T.G., Lee, C.H., and Kim, K.S. (2018). Metformin inhibits the development of L-dopa-induced dyskinesia in a murine model of Parkinson\u2019s disease. Mol. Neurobiol. 55: 5715\u20135726, https:\/\/doi.org\/10.1007\/s12035-017-0752-7.","DOI":"10.1007\/s12035-017-0752-7"},{"key":"2023100409531721958_j_revneuro-2022-0093_ref_121","doi-asserted-by":"crossref","unstructured":"Schapira, A.H. (2008). Mitochondria in the aetiology and pathogenesis of Parkinson\u2019s disease. Lancet Neurol. 7: 97\u2013109, https:\/\/doi.org\/10.1016\/s1474-4422(07)70327-7.","DOI":"10.1016\/S1474-4422(07)70327-7"},{"key":"2023100409531721958_j_revneuro-2022-0093_ref_122","doi-asserted-by":"crossref","unstructured":"Sekiyama, K., Waragai, M., Akatsu, H., Sugama, S., Takenouchi, T., Takamatsu, Y., Fujita, M., Sekigawa, A., Rockenstein, E., Inoue, S., et al.. (2014). Disease-modifying effect of adiponectin in model of \u03b1-synucleinopathies. Ann. Clin. Transl. Neurol. 1: 479\u2013489, https:\/\/doi.org\/10.1002\/acn3.77.","DOI":"10.1002\/acn3.77"},{"key":"2023100409531721958_j_revneuro-2022-0093_ref_123","doi-asserted-by":"crossref","unstructured":"Shannon, K.M., Keshavarzian, A., Dodiya, H.B., Jakate, S., and Kordower, J.H. (2012). Is alpha-synuclein in the colon a biomarker for premotor Parkinson\u2019s disease? Evidence from 3 cases. Mov. Disord. 27: 716\u2013719, https:\/\/doi.org\/10.1002\/mds.25020.","DOI":"10.1002\/mds.25020"},{"key":"2023100409531721958_j_revneuro-2022-0093_ref_124","doi-asserted-by":"crossref","unstructured":"Sharma, S.K., Chorell, E., Steneberg, P., Vernersson-Lindahl, E., Edlund, H., and Wittung-Stafshede, P. (2015). Insulin-degrading enzyme prevents \u03b1-synuclein fibril formation in a nonproteolytical manner. Sci. Rep. 5: 12531, https:\/\/doi.org\/10.1038\/srep12531.","DOI":"10.1038\/srep12531"},{"key":"2023100409531721958_j_revneuro-2022-0093_ref_125","doi-asserted-by":"crossref","unstructured":"Shi, Q., Liu, S., Fonseca, V.A., Thethi, T.K., and Shi, L. (2019). Effect of metformin on neurodegenerative disease among elderly adult US veterans with type 2 diabetes mellitus. BMJ Open 9: e024954, https:\/\/doi.org\/10.1136\/bmjopen-2018-024954.","DOI":"10.1136\/bmjopen-2018-024954"},{"key":"2023100409531721958_j_revneuro-2022-0093_ref_126","doi-asserted-by":"crossref","unstructured":"Shola-Dare, O., Bailess, S., Flores, C.C., Vanderheyden, W.M., and Gerstner, J.R. (2021). Glitazone treatment rescues phenotypic deficits in a fly model of Gaucher\/Parkinson\u2019s disease. Int. J.\u00a0Mol. Sci. 22, https:\/\/doi.org\/10.3390\/ijms222312740.","DOI":"10.3390\/ijms222312740"},{"key":"2023100409531721958_j_revneuro-2022-0093_ref_127","doi-asserted-by":"crossref","unstructured":"Sierra, S., Ramos, M.C., Molina, P., Esteo, C., V\u00e1zquez, J.A., and Burgos, J.S. (2011). Statins as neuroprotectants: a comparative in\u00a0vitro study of lipophilicity, blood-brain-barrier penetration, lowering of brain cholesterol, and decrease of neuron cell death. J.\u00a0Alzheimer\u2019s Dis. 23: 307\u2013318, https:\/\/doi.org\/10.3233\/jad-2010-101179.","DOI":"10.3233\/JAD-2010-101179"},{"key":"2023100409531721958_j_revneuro-2022-0093_ref_128","doi-asserted-by":"crossref","unstructured":"Stark, R. and Roden, M. (2007). ESCI Award 2006. Mitochondrial function and endocrine diseases. Eur. J.\u00a0Clin. Invest. 37: 236\u2013248, https:\/\/doi.org\/10.1111\/j.1365-2362.2007.01773.x.","DOI":"10.1111\/j.1365-2362.2007.01773.x"},{"key":"2023100409531721958_j_revneuro-2022-0093_ref_129","doi-asserted-by":"crossref","unstructured":"Steneberg, P., Bernardo, L., Edfalk, S., Lundberg, L., Backlund, F., Ostenson, C.G., and Edlund, H. (2013). The type 2 diabetes-associated gene ide is required for insulin secretion and suppression of \u03b1-synuclein levels in \u03b2-cells. Diabetes 62: 2004\u20132014, https:\/\/doi.org\/10.2337\/db12-1045.","DOI":"10.2337\/db12-1045"},{"key":"2023100409531721958_j_revneuro-2022-0093_ref_130","doi-asserted-by":"crossref","unstructured":"Sun, M.F., Zhu, Y.L., Zhou, Z.L., Jia, X.B., Xu, Y.D., Yang, Q., Cui, C., and Shen, Y.Q. (2018). Neuroprotective effects of fecal microbiota transplantation on MPTP-induced Parkinson\u2019s disease mice: Gut microbiota, glial reaction and TLR4\/TNF-\u03b1 signaling pathway. Brain Behav. Immun. 70: 48\u201360, https:\/\/doi.org\/10.1016\/j.bbi.2018.02.005.","DOI":"10.1016\/j.bbi.2018.02.005"},{"key":"2023100409531721958_j_revneuro-2022-0093_ref_131","doi-asserted-by":"crossref","unstructured":"Surmeier, D.J. (2007). Calcium, ageing, and neuronal vulnerability in Parkinson\u2019s disease. Lancet Neurol. 6: 933\u2013938, https:\/\/doi.org\/10.1016\/s1474-4422(07)70246-6.","DOI":"10.1016\/S1474-4422(07)70246-6"},{"key":"2023100409531721958_j_revneuro-2022-0093_ref_132","doi-asserted-by":"crossref","unstructured":"Surmeier, D.J., Guzman, J.N., Sanchez-Padilla, J., and Goldberg, J.A. (2011). The origins of oxidant stress in Parkinson\u2019s disease and therapeutic strategies. Antioxid. Redox Signaling 14: 1289\u20131301, https:\/\/doi.org\/10.1089\/ars.2010.3521.","DOI":"10.1089\/ars.2010.3521"},{"key":"2023100409531721958_j_revneuro-2022-0093_ref_133","doi-asserted-by":"crossref","unstructured":"Svenningsson, P., Wirdefeldt, K., Yin, L., Fang, F., Markaki, I., Efendic, S., and Ludvigsson, J.F. (2016). Reduced incidence of Parkinson\u2019s disease after dipeptidyl peptidase-4 inhibitors: a nationwide case-control study. Mov. Disord. 31: 1422\u20131423, https:\/\/doi.org\/10.1002\/mds.26734.","DOI":"10.1002\/mds.26734"},{"key":"2023100409531721958_j_revneuro-2022-0093_ref_134","doi-asserted-by":"crossref","unstructured":"Swanson, C. and Emborg, M. (2014). Expression of peroxisome proliferator-activated receptor-gamma in the substantia nigra of hemiparkinsonian nonhuman primates. Neurol. Res. 36: 634\u2013646, https:\/\/doi.org\/10.1179\/1743132813y.0000000305.","DOI":"10.1179\/1743132813Y.0000000305"},{"key":"2023100409531721958_j_revneuro-2022-0093_ref_135","doi-asserted-by":"crossref","unstructured":"S\u00e4\u00e4ksj\u00e4rvi, K., Knekt, P., M\u00e4nnist\u00f6, S., Lyytinen, J., and Heli\u00f6vaara, M. (2015). Prospective study on the components of metabolic syndrome and the incidence of Parkinson\u2019s disease. Parkinsonism Relat. Disord. 21: 1148\u20131155, https:\/\/doi.org\/10.1016\/j.parkreldis.2015.07.017.","DOI":"10.1016\/j.parkreldis.2015.07.017"},{"key":"2023100409531721958_j_revneuro-2022-0093_ref_136","doi-asserted-by":"crossref","unstructured":"Thirumangalakudi, L., Prakasam, A., Zhang, R., Bimonte-Nelson, H., Sambamurti, K., Kindy, M.S., and Bhat, N.R. (2008). High cholesterol-induced neuroinflammation and amyloid precursor protein processing correlate with loss of working memory in mice. J.\u00a0Neurochem. 106: 475\u2013485, https:\/\/doi.org\/10.1111\/j.1471-4159.2008.05415.x.","DOI":"10.1111\/j.1471-4159.2008.05415.x"},{"key":"2023100409531721958_j_revneuro-2022-0093_ref_137","doi-asserted-by":"crossref","unstructured":"Tohgi, H., Utsugisawa, K., Yoshimura, M., Nagane, Y., and Mihara, M. (1998). Alterations with aging and ischemia in nicotinic acetylcholine receptor subunits \u03b14 and \u03b22 messenger RNA expression in postmortem human putamen. Implications for susceptibility to parkinsonism. Brain Res. 791: 186\u2013190, https:\/\/doi.org\/10.1016\/s0006-8993(98)00093-6.","DOI":"10.1016\/S0006-8993(98)00093-6"},{"key":"2023100409531721958_j_revneuro-2022-0093_ref_138","doi-asserted-by":"crossref","unstructured":"Trayhurn, P. (2022). Adipokines: inflammation and the pleiotropic role of white adipose tissue. Br. J.\u00a0Nutr. 127: 161\u2013164, https:\/\/doi.org\/10.1017\/s0007114521003962.","DOI":"10.1017\/S0007114521003962"},{"key":"2023100409531721958_j_revneuro-2022-0093_ref_062","doi-asserted-by":"crossref","unstructured":"van IJzendoorn, S. and Derkinderen, P. (2019). The intestinal barrier in Parkinson\u2019s disease: current state of knowledge. J.\u00a0Parkinson\u2019s Dis. 9: S323\u2013S329, https:\/\/doi.org\/10.3233\/jpd-191707.","DOI":"10.3233\/JPD-191707"},{"key":"2023100409531721958_j_revneuro-2022-0093_ref_139","doi-asserted-by":"crossref","unstructured":"Wakabayashi, K. and Takahashi, H. (1997). Neuropathology of autonomic nervous system in Parkinson\u2019s disease. Eur. Neurol. 38(Suppl. 2): 2\u20137, https:\/\/doi.org\/10.1159\/000113469.","DOI":"10.1159\/000113469"},{"key":"2023100409531721958_j_revneuro-2022-0093_ref_140","doi-asserted-by":"crossref","unstructured":"Wan, R., Ahmet, I., Brown, M., Cheng, A., Kamimura, N., Talan, M., and Mattson, M.P. (2010). Cardioprotective effect of intermittent fasting is associated with an elevation of adiponectin levels in rats. J.\u00a0Nutr. Biochem. 21: 413\u2013417, https:\/\/doi.org\/10.1016\/j.jnutbio.2009.01.020.","DOI":"10.1016\/j.jnutbio.2009.01.020"},{"key":"2023100409531721958_j_revneuro-2022-0093_ref_141","doi-asserted-by":"crossref","unstructured":"Wang, K., Luo, Z., Li, C., Huang, X., Shiroma, E.J., Simonsick, E.M., and Chen, H. (2021). Blood cholesterol decreases as Parkinson\u2019s disease develops and progresses. J.\u00a0Parkinson\u2019s Dis. 11: 1177\u20131186, https:\/\/doi.org\/10.3233\/jpd-212670.","DOI":"10.3233\/JPD-212670"},{"key":"2023100409531721958_j_revneuro-2022-0093_ref_142","doi-asserted-by":"crossref","unstructured":"Wang, Y., Zhao, W., Li, G., Chen, J., Guan, X., Chen, X., and Guan, Z. (2017). Neuroprotective effect and mechanism of thiazolidinedione on dopaminergic neurons in vivo and in vitro in Parkinson\u2019s disease. PPAR Res. 2017: 4089214, https:\/\/doi.org\/10.1155\/2017\/4089214.","DOI":"10.1155\/2017\/4089214"},{"key":"2023100409531721958_j_revneuro-2022-0093_ref_143","doi-asserted-by":"crossref","unstructured":"Weng, Z., Signore, A.P., Gao, Y., Wang, S., Zhang, F., Hastings, T., Yin, X.M., and Chen, J. (2007). Leptin protects against 6-hydroxydopamine-induced dopaminergic cell death via mitogen-activated protein kinase signaling. J.\u00a0Biol. Chem. 282: 34479\u201334491, https:\/\/doi.org\/10.1074\/jbc.m705426200.","DOI":"10.1074\/jbc.M705426200"},{"key":"2023100409531721958_j_revneuro-2022-0093_ref_144","doi-asserted-by":"crossref","unstructured":"Whitmer, R.A., Gunderson, E.P., Barrett-Connor, E., QuesenberryJr, C.P., and Yaffe, K. (2005). Obesity in middle age and future risk of dementia: a 27 year longitudinal population based study. BMJ 330: 1360, https:\/\/doi.org\/10.1136\/bmj.38446.466238.e0.","DOI":"10.1136\/bmj.38446.466238.E0"},{"key":"2023100409531721958_j_revneuro-2022-0093_ref_145","doi-asserted-by":"crossref","unstructured":"Wills, J., Jones, J., Haggerty, T., Duka, V., Joyce, J.N., and Sidhu, A. (2010). Elevated tauopathy and alpha-synuclein pathology in postmortem Parkinson\u2019s disease brains with and without dementia. Exp. Neurol. 225: 210\u2013218, https:\/\/doi.org\/10.1016\/j.expneurol.2010.06.017.","DOI":"10.1016\/j.expneurol.2010.06.017"},{"key":"2023100409531721958_j_revneuro-2022-0093_ref_146","doi-asserted-by":"crossref","unstructured":"Wolf, A.M., Wolf, D., Rumpold, H., Enrich, B., and Tilg, H. (2004). Adiponectin induces the anti-inflammatory cytokines IL-10 and IL-1RA in human leukocytes. Biochem. Biophys. Res. Commun. 323: 630\u2013635, https:\/\/doi.org\/10.1016\/j.bbrc.2004.08.145.","DOI":"10.1016\/j.bbrc.2004.08.145"},{"key":"2023100409531721958_j_revneuro-2022-0093_ref_147","doi-asserted-by":"crossref","unstructured":"Wulster-Radcliffe, M.C., Ajuwon, K.M., Wang, J., Christian, J.A., and Spurlock, M.E. (2004). Adiponectin differentially regulates cytokines in porcine macrophages. Biochem. Biophys. Res. Commun. 316: 924\u2013929, https:\/\/doi.org\/10.1016\/j.bbrc.2004.02.130.","DOI":"10.1016\/j.bbrc.2004.02.130"},{"key":"2023100409531721958_j_revneuro-2022-0093_ref_148","doi-asserted-by":"crossref","unstructured":"Xu, Q., Park, Y., Huang, X., Hollenbeck, A., Blair, A., Schatzkin, A., and Chen, H. (2011). Diabetes and risk of Parkinson\u2019s disease. Diabetes Care 34: 910\u2013915, https:\/\/doi.org\/10.2337\/dc10-1922.","DOI":"10.2337\/dc10-1922"},{"key":"2023100409531721958_j_revneuro-2022-0093_ref_149","doi-asserted-by":"crossref","unstructured":"Yuan, Z., Li, D., Feng, P., Xue, G., Ji, C., Li, G., and H\u00f6lscher, C. (2017). A\u00a0novel GLP-1\/GIP dual agonist is more effective than liraglutide in reducing inflammation and enhancing GDNF release in the MPTP mouse model of Parkinson\u2019s disease. Eur. J.\u00a0Pharmacol. 812: 82\u201390, https:\/\/doi.org\/10.1016\/j.ejphar.2017.06.029.","DOI":"10.1016\/j.ejphar.2017.06.029"},{"key":"2023100409531721958_j_revneuro-2022-0093_ref_150","doi-asserted-by":"crossref","unstructured":"Zhang, F., Qian, L., Flood, P.M., Shi, J.S., Hong, J.S., and Gao, H.M. (2010). Inhibition of I\u03baBeta kinase-\u03b2 protects dopamine neurons against lipopolysaccharide-induced neurotoxicity. J.\u00a0Pharmacol. Exp. Ther. 333: 822\u2013833, https:\/\/doi.org\/10.1124\/jpet.110.165829.","DOI":"10.1124\/jpet.110.165829"},{"key":"2023100409531721958_j_revneuro-2022-0093_ref_151","doi-asserted-by":"crossref","unstructured":"Zhao, H., Zhuo, L., Sun, Y., Shen, P., Lin, H., and Zhan, S. (2022). Thiazolidinedione use and risk of Parkinson\u2019s disease in patients with type 2 diabetes mellitus. NPJ Parkinson\u2019s Dis. 8: 138, https:\/\/doi.org\/10.1038\/s41531-022-00406-8.","DOI":"10.1038\/s41531-022-00406-8"},{"key":"2023100409531721958_j_revneuro-2022-0093_ref_152","doi-asserted-by":"crossref","unstructured":"Zhao, Y., Jia, M., Chen, W., and Liu, Z. (2022). The neuroprotective effects of intermittent fasting on brain aging and neurodegenerative diseases via regulating mitochondrial function. Free Radic. Biol. Med. 182: 206\u2013218, https:\/\/doi.org\/10.1016\/j.freeradbiomed.2022.02.021.","DOI":"10.1016\/j.freeradbiomed.2022.02.021"}],"container-title":["Reviews in the Neurosciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/revneuro-2022-0093\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/revneuro-2022-0093\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,4]],"date-time":"2023-10-04T09:55:45Z","timestamp":1696413345000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/revneuro-2022-0093\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,2]]},"references-count":152,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2023,5,18]]},"published-print":{"date-parts":[[2023,10,26]]}},"alternative-id":["10.1515\/revneuro-2022-0093"],"URL":"https:\/\/doi.org\/10.1515\/revneuro-2022-0093","relation":{},"ISSN":["0334-1763","2191-0200"],"issn-type":[{"value":"0334-1763","type":"print"},{"value":"2191-0200","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,2]]}}}